{"nctId":"NCT00002597","briefTitle":"Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer","startDateStruct":{"date":"1994-10"},"conditions":["Prostate Cancer"],"count":2028,"armGroups":[{"label":"Neoadjuvant TAS + RT","type":"EXPERIMENTAL","interventionNames":["Drug: flutamide","Drug: Zoladex","Drug: Lupron","Radiation: radiation therapy"]},{"label":"Radiation therapy alone","type":"OTHER","interventionNames":["Radiation: radiation therapy"]}],"interventions":[{"name":"flutamide","otherNames":["Eulexin"]},{"name":"Zoladex","otherNames":["goserelin acetate"]},{"name":"Lupron","otherNames":["leuprolide acetate"]},{"name":"radiation therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Histologically confirmed locally confined adenocarcinoma of the prostate with primary tumors confined to the prostate, clinical stage T1b,1c, 2a or 2b.\n* Negative nodes evaluated by imaging methods (classified in the study as NX) or by surgical sampling (classified in the study as N0).\n* Karnofsky performance status ≥ 70.\n* PSA is mandatory, must be ≤ 20)\n* No prior hormonal therapy, radiation or chemotherapy.\n* Prior finasteride for prostate hypertrophy allowed if discontinued at least 60 days prior to randomization.\n* Prior testosterone administration allowed if at least 90 days elapsed since last administration.\n* No evidence of distant metastasis or other synchronous primary. Patients with prior invasive malignancy who were disease free for at least 5 years could be eligible with pre-randomization approval by the study chairman.\n* Treatment begins within 21 days after randomization.\n* Patients signs a study-specific informed consent form.\n* Alanine Aminotransferase (ALT) within 2x upper normal limits.\n\nExclusion criteria:\n\n* Stage T1a or ≥ T2c disease.\n* Lymph node involvement (N1 - N3).\n* Evidence of distant metastasis. (M1)\n* PSA \\> 20.\n* Radical surgery or cryosurgery for carcinoma of the prostate, previous irradiation, antiandrogen therapy or chemotherapy.\n* Previous or concurrent cancers other than basal cell or squamous cell skin carcinoma.\n\nPatients with squamous cell carcinomas required to be NED (no evidence of disease) for a minimum of two years prior to study entry.\n\n* Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.\n* Karnofsky performance status of \\< 70.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival Rate (10-year)","description":"Overall survival (OS) was calculated from randomization to the date of death from any cause and overall survival rates were estimated by the Kaplan-Meier method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null},{"groupId":"OG001","value":"56.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-specific Survival Rate (10 Years)","description":"Disease-specific failure is defined as death certified as due to prostate cancer (by central review), death due to complications of treatment (irrespective of malignancy status), death from unknown causes with active malignancy, or death from unknown causes with previously documented relapse (either clinical or biochemical). Survival rates were estimated by means of cumulative incidence functions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"92.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Progression Rate (10 Years)","description":"Local progression defined as documented local progression as determined by clinical exam . Failure rates were estimated by means of cumulative incidence functions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"16.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Distant Failure Rate (10 Years)","description":"Failure is defined as documented metastatic disease. Failure rates were estimated by means of cumulative incidence functions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Biochemical Failure Rate (10 Years)","description":"The Phoenix definition of biochemical failure was used - an increase in the prostate-specific antigen (PSA) level of \\>2 ng per milliliter above the nadir. Failure rates were estimated by means of cumulative incidence functions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"41.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Relapse Rate (10 Years)","description":"Clinical relapse is defined as local progression or distant metastases. Failure rates were estimated by means of cumulative incidence functions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"21.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Second Biochemical Relapse Rate (10 Years)","description":"Second biochemical relapse is as defined as follows (after initiation of salvage hormone therapy): A rise in PSA on at least two consecutive cases above the nadir (after initiation of salvage hormone therapy), with the rises in PSA exceeding 1 ng/ml above the nadir; or failure to reach 4 ng/L or less at 18 months. The rates of second biochemical relapse were estimated by means of cumulative incidence functions.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival Rate (10 Years)","description":"Disease-free failure is defined as documentation of progression (local progression, distant failure, and biochemical failure) or death from any cause. Disease-free survival rates were estimated by the Kaplan-Meier method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Positive Re-biopsy Rate at Two Years","description":"The rate of prostate rebiopsy at two years is defined as the proportion of patients whose results are positive among all eligible patients who had a repeat biopsy at two years. The rate was estimated separately in each arm.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"38.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":1003},"commonTop":["Acute RT Toxicity: Bowel: NOS","Late RT Toxicity: Bowel: NOS","Late RT Toxicity: Bladder: NOS","Acute RT Toxicity: Bladder: NOS","Hormone Toxicity: Hot flashes : NOS"]}}}